Adempas (riociguat)

Manufacturer:

Bayer

Route of Administration:

Oral

Site of Care:

Outpatient

Website:

phone:

Enrollment Forms:

Patient Support Form

VA Enrollment Form

Approved Indication:

persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and functional class
pulmonary arterial hypertension (WHO group 1) to improve exercise capacity, improve functional class, and delay clinical worsening

Conditions:

Chronic Thromboembolic Pulmonary Hypertension
Pulmonary Arterial Hypertension